Carl Icahn Plans to Acquire Stake in Hologic; Company Responds with Poison Pill | GenomeWeb

NEW YORK (GenomeWeb News) – Following notification by a hedge fund headed by Carl Icahn of its intentions to acquire a stake in Hologic, the Bedford, Mass.-based firm today announced it has adopted a stockholder rights plan "intended to ensure that the board remains in the best position to perform its fiduciary duties and to enable all Hologic stockhoders to receive fair and equal treatment."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.